Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy

EMBO Molecular Medicine

Volumn 7, Issue 12, 2015, Pages 1513-1528

  Cossu, Giulio ^a   Previtali, Stefano C ^b   Napolitano, Sara ^b   Cicalese, Maria Pia ^b   Tedesco, Francesco Saverio ^c   Nicastro, Francesca ^b,d   Noviello, Maddalena ^b   Roostalu, Urmas ^a   Natali Sora, Maria Grazia ^b   Scarlato, Marina ^b   De Pellegrin, Maurizio ^b   Godi, Claudia ^b,d   Giuliani, Serena ^b   Ciotti, Francesca ^b   Tonlorenzi, Rossana ^b   Lorenzetti, Isabella ^b   Rivellini, Cristina ^b   Benedetti, Sara ^c   Gatti, Roberto ^b   Marktel, Sarah ^b   Mazzi, Benedetta ^b   Tettamanti, Andrea ^b   Ragazzi, Martina ^c   Imro, Maria Adele ^e   Marano, Giuseppina ^e   Ambrosi, Alessandro ^f   Fiori, Rossana ^b   Sormani, Maria Pia ^g   Bonini, Chiara ^b   Venturini, Massimo ^b   Politi, Letterio S ^b   Torrente, Yvan ^d   Ciceri, Fabio ^b   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MILAN   (Italy)

^e MOLMED S P A   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

Cell therapy; Duchenne; Dystrophin; Mesoangioblast; MRI

Indexed keywords

DEFLAZACORT; DNA; DYSTROPHIN; PREDNISONE; TACROLIMUS;

ARTICLE; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; HLA MATCHING; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MESOANGIOBLAST; MUSCLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; BIOLOGICAL THERAPY; HISTOCOMPATIBILITY TEST; INTRAARTERIAL DRUG ADMINISTRATION; MUSCULAR DYSTROPHY, DUCHENNE; UTILIZATION;

CELL- AND TISSUE-BASED THERAPY; HISTOCOMPATIBILITY TESTING; HUMANS; INFUSIONS, INTRA-ARTERIAL; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84954401426     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201505636     Document Type: Article

References (47)

1. Arechavala-Gomeza V, Kinali M, Feng L, Brown SC, Sewry C, Morgan JE, Muntoni F (2010) Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. Neuropathol Appl Neurobiol 36: 265-274
2. Benedetti S, Hoshiya H, Tedesco FS (2013) Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies. FEBS J 280: 4263-4280
3. Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, Connolly AM, Day JW, Flanigan KM, Goemans N et al (2014) Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50: 477-487
4. Buyse GM, Voit T, Schara U, Straathof CS, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, McDonald CM et al (2015) Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet 385: 1748-1757
5. Davies KE, Nowak KJ (2006) Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 7: 762-773
6. Dellavalle A, Sampaolesi M, Tonlorenzi R, Tagliafico E, Sacchetti B, Perani L, Innocenzi A, Galvez BG, Messina G, Morosetti R et al (2007) Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol 9: 255-267
7. Dellavalle A, Maroli G, Covarello D, Azzoni E, Innocenzi A, Perani L, Antonini S, Sambasivan R, Brunelli S, Tajbakhsh S et al (2011) Pericytes resident in postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells. Nat Commun 2: 499
8. Diaz-Manera J, Touvier T, Dellavalle A, Tonlorenzi R, Tedesco FS, Messina G, Meregalli M, Navarro C, Perani L, Bonfanti C et al (2010) Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy. Cell Death Dis 1: e61
9. Domi T, Porrello E, Velardo D, Capotondo A, Biffi A, Tonlorenzi R, Amadio S, Ambrosi A, Miyagoe-Suzuki Y, Takeda S et al (2015) Mesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A. Skelet Muscle 3: 30
10. Ebinger F, Boor R, Gawehn J, Reitter B (1999) Ischemic stroke and migraine in childhood: coincidence or causal relation? J Child Neurol 14: 451-455
11. Egli A, Kumar D, Broscheit C, O'Shea D, Humar A (2013) Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. Transplantation 95: 448-455
12. Flanigan KM, Campbell K, Viollet L, Wang W, Gomez AM, Walker CM, Mendell JR (2013) Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther 24: 797-806
13. Garg BP, DeMyer WE (1995) Ischemic thalamic infarction in children: clinical presentation, etiology, and outcome. Pediatr Neurol 13: 46-49
14. Gehrz RC, Fuad S, Liu YN, Bach FH (1987) HLA class II restriction of T helper cell response to cytomegalovirus (CMV). I. Immunogenetic control of restriction. J Immunol 138: 3145-3151
15. Hanajima R, Kawai M (1996) Incidence of cerebral infarction in Duchenne muscular dystrophy. Muscle Nerve 19: 928
16. Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928
17. Kristt D, Israeli M, Narinski R, Or H, Yaniv I, Stein J, Klein T (2005) Hematopoietic chimerism monitoring based on STRs: quantitative platform performance on sequential samples. J Biomol Tech 16: 380-391
18. Kurth T, Chabriat H, Bousser MG (2012) Migraine and stroke: a complex association with clinical implications. Lancet Neurol 11: 92-100
19. Lerario A, Bonfiglio S, Sormani M, Tettamanti A, Marktel S, Napolitano S, Previtali S, Scarlato M, Natali-Sora M, Mercuri E et al (2012) Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures. BMC Neurol 12: 91
20. Leung DG, Wagner KR (2013) Therapeutic advances in muscular dystrophy. Ann Neurol 74: 404-411
21. Leung DG, Herzka DA, Thompson WR, He B, Bibat G, Tennekoon G, Russell SD, Schuleri KH, Lardo AC, Kass DA et al (2014) Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann Neurol 76: 541-549
22. Manzur AY, Kuntzer T, Pike M, Swan A (2008) Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev CD003725
23. Manzur AY, Muntoni F (2009) Diagnosis and new treatments in muscular dystrophies. J Neurol Neurosurg Psychiatry 80: 706-714
24. Mazzone E, Vasco G, Sormani MP, Torrente Y, Berardinelli A, Messina S, D'Amico A, Doglio L, Politano L, Cavallaro F et al (2011) Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 77: 250-256
25. Mercuri E, Muntoni F (2013a) Muscular dystrophies. Lancet 381: 845-860
26. Mercuri E, Muntoni F (2013b) Muscular dystrophy: new challenges and review of the current clinical trials. Curr Opin Pediatr 25: 701-707
27. Minasi MG, Riminucci M, De Angelis L, Borello U, Berarducci B, Innocenzi A, Caprioli A, Sirabella D, Baiocchi M, De Maria R et al (2002) The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 129: 2773-2783
28. Muntoni F (2003) Cardiac complications of childhood myopathies. J Child Neurol 18: 191-202
29. Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2: 731-740
30. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239-245
31. Noviello M, Tedesco FS, Bondanza A, Tonlorenzi R, Rosaria Carbone M, Gerli MF, Marktel S, Napolitano S, Cicalese MP, Ciceri F et al (2014) Inflammation converts human mesoangioblasts into targets of alloreactive immune responses: implications for allogeneic cell therapy of DMD. Mol Ther 22: 1342-1352
32. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP (2011) Integrative genomics viewer. Nat Biotechnol 29: 24-26
33. Ruegg UT (2013) Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr Opin Neurol 26: 577-584
34. Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, Vittecoq D, Salmon D, Amoura Z, Katlama C, Autran B (2005) Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med 201: 1999-2010
35. Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D'Antona G, Pellegrino MA, Barresi R, Bresolin N, De Angelis MG, Campbell KP et al (2003) Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301: 487-492
36. Sampaolesi M, Blot S, D'Antona G, Granger N, Tonlorenzi R, Innocenzi A, Mognol P, Thibaud JL, Galvez BG, Barthelemy I et al (2006) Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444: 574-579
37. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP (2007) Stem cell transplantation: the lung barrier. Transpl Proc 39: 573-576
38. Schueren F, Lingner T, George R, Hofhuis J, Dickel C, Gartner J, Thoms S (2014) Peroxisomal lactate dehydrogenase is generated by translational readthrough in mammals. Elife 3: e03640
39. Seto JT, Bengtsson NE, Chamberlain JS (2014) Therapy of genetic disorders-novel therapies for duchenne muscular dystrophy. Curr Pediatr Rep 2: 102-112
40. Sharma RR, Pollock K, Hubel A, McKenna D (2014) Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 54: 1418-1437
41. Tedesco FS, Hoshiya H, D'Antona G, Gerli MF, Messina G, Antonini S, Tonlorenzi R, Benedetti S, Berghella L, Torrente Y et al (2011) Stem cell-mediated transfer of a human artificial chromosome ameliorates muscular dystrophy. Sci Transl Med 3: 96ra78.
42. Tedesco FS, Gerli MF, Perani L, Benedetti S, Ungaro F, Cassano M, Antonini S, Tagliafico E, Artusi V, Longa E et al (2012) Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci Transl Med 4: 140ra189.
43. Thorvaldsdottir H, Robinson JT, Mesirov JP (2013) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14: 178-192
44. Tonlorenzi R, Dellavalle A, Schnapp E, Cossu G, Sampaolesi M (2007) Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues. Curr Protoc Stem Cell Biol Chapter 2: Unit 2B 1
45. Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, De Kimpe SJ, Eagle M, Guglieri M, Hood S et al (2014) Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol 13: 987-996
46. Witting N, Kruuse C, Nyhuus B, Prahm KP, Citirak G, Lundgaard SJ, von Huth S, Vejlstrup N, Lindberg U, Krag TO et al (2014) Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy. Ann Neurol 76: 550-557
47. Ye S, Dhillon S, Ke X, Collins AR, Day IN (2001) An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 29: E88-E88